Zharp1-163 是一种铁死亡 (ferroptosis) 和坏死性凋亡 (necroptosis) 的双重抑制剂,它通过降低活性氧 (ROS) 水平有效阻断铁死亡,并通过强效且选择性地靶向 RIPK1 激酶活性 (KD = 240 nM; IC50 = 406.1 nM) 来抑制坏死性凋亡,同时抑制坏死性凋亡刺激引起的 RIPK1、RIPK3 和 MLKL 的细胞活化,还能显著减轻 TNF-α (MS-C61116) 诱导的全身炎症综合征(包括预防 TNF-α 诱导的小鼠死亡和体温过低),并显著减轻 Cisplatin (MS-E94993) 和缺血再灌注诱导的模型中与坏死性凋亡和铁死亡相关的急性肾损伤,因此可用于研究与细胞死亡通路相关的疾病,例如肾脏疾病。
Zharp1-163
产品编号: MS-A34854 分子式: C21H23N5O3 分子量: 393.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Zharp1-163 是一种铁死亡 (ferroptosis) 和坏死性凋亡 (necroptosis) 的双重抑制剂,它通过降低活性氧 (ROS) 水平有效阻断铁死亡,并通过强效且选择性地靶向 RIPK1 激酶活性 (KD = 240 nM; IC50 = 406.1 nM) 来抑制坏死性凋亡,同时抑制坏死性凋亡刺激引起的 RIPK1、RIPK3 和 MLKL 的细胞活化,还能显著减轻 TNF-α (MS-C61116) 诱导的全身炎症综合征(包括预防 TNF-α 诱导的小鼠死亡和体温过低),并显著减轻 Cisplatin (MS-E94993) 和缺血再灌注诱导的模型中与坏死性凋亡和铁死亡相关的急性肾损伤,因此可用于研究与细胞死亡通路相关的疾病,例如肾脏疾病。

生物实验数据

生物活性 Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis that effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (KD = 240 nM; IC50 = 406.1 nM), suppresses necroptosis-stimulus-induced cellular activation of RIPK1, RIPK3, and MLKL, significantly alleviates TNF-α (MS-C61116)-induced systemic inflammatory response syndrome, including prevention of TNF-α-induced mortality and hypothermia in mice, and markedly attenuates necroptosis- and ferroptosis-associated acute kidney injury in Cisplatin (MS-E94993)- and ischemia-reperfusion-induced models, and can therefore be used for research on diseases associated with cell death pathways, such as kidney diseases.
IC50 & Target

RIPK1

240 nM (Kd)

RIPK1

406.1 nM (IC50)

RIPK3

 

体外研究
(In Vitro)

Zharp1-163 (0.01-10 μM,18 小时) 显著抑制 Erastin (MS-C46386) 或 RSL3 (MS-V15144) 诱导的 HT-1080 细胞 (EC50 = 0.95 μM;EC50 = 1.33 μM) 和小鼠胚胎成纤维细胞 (MEF) (EC50 = 1.93 μM;EC50 = 1.39 μM) 中的铁死亡。
Zharp1-163 (0.01-10 μM,14-18 小时) 阻断 TNF-α、Smac 模拟物和 Z-VAD (MS-V02713) 诱导的 HT-29 细胞 (EC50 = 0.1 μM) 和 MEF (EC50 = 0.11 μM) 中的坏死性凋亡。
Zharp1-163 (0.01-10 μM,14 小时) 能有效抑制小鼠成纤维细胞 L929 中 TNFα 和 Z-VAD 诱导的坏死性凋亡。
Zharp1-163 (0.3-3 μM,26 小时) 能抑制 TNFα 联合 Smac 模拟物诱导的 MEF 细胞凋亡。
Zharp1-163 (0.3-3 μM,8 小时) 对 THP-1 细胞的细胞焦亡无影响。
Zharp1-163 (10 μM,7 小时) 能显著降低铁死亡过程中脂质 ROS 的产生,并降低 RSL3 诱导的 HT-1080 细胞中 CHAC1 和 PTGS2 的表达。
Zharp1-163 (0.1-3 μM,10 小时) 可消除人 HT-29 细胞中 RIPK1、RIPK3 和 MLKL 的磷酸化,并阻断 MEF 细胞中 RIPK1、RIPK3 和 MLKL 的磷酸化。
Zharp1-163 (0.3-3 μM,10 小时) 可抑制 HT-29 细胞中 RIPK3 斑点的形成和 MLKL 的寡聚化。

Cell Viability Assay

Cell Line: HT-1080 cells and MEFs.
Concentration: 0.01 μM, 0.1 μM, 1 μM, 10 μM
Incubation Time: Pretreated 2 h and then treated with Erastin or RSL3 for 16 h
Result: Significantly inhibited Erastin- or RSL3-induced ferroptosis in HT-1080 cells and MEFs.

Cell Viability Assay

Cell Line: HT-1080 cells and MEFs.
Concentration: 0.01 μM, 0.1 μM, 1 μM
Incubation Time: Pretreated 2 h, followed by treatment with TNF-α (T) (40 ng/mL), Smac mimetic (S) (100 nM), Z-VAD (Z) (20 μM) for 12-16 h
Result: Blocked TNF-α, Smac mimetic, and Z-VAD-induced necroptosis in HT-29 cells (EC50 = 0.1 μM), in MEFs (EC50 = 0.11 μM).

Cell Viability Assay

Cell Line: Mouse fibroblast L929 cells
Concentration: 0.01 μM, 0.1 μM, 1 μM
Incubation Time: 2 h, followed by treatment with T (40 ng/mL) and Z (20 μM) for 12 h
Result: Blocked TNF-α, Z-VAD-induced necroptosis in mouse fibroblast L929 cells (EC50 = 0.08 μM).

Apoptosis Analysis

Cell Line: MEFs
Concentration: 0.3 μM, 1 μM, 3 μM
Incubation Time: 2 h before treatment with T (40 ng/mL) and S (100 nM) for 24 h
Result: Inhibited apoptosis induced by TNFα plus Smac mimetic in MEFs.

Real Time qPCR

Cell Line: HT-1080 cells
Concentration: 10 μM
Incubation Time: 2 h, followed by induction with RSL3 for 5 h
Result: Significantly reduced the induction of both CHAC1 and PTGS2 in response to RSL3.

Western Blot Analysis

Cell Line: HT-29 cells, MEFs
Concentration: 0.1 μM, 0.3 μM, 1 μM, 3 μM
Incubation Time: 2 h, followed by treatment with T (40 ng/mL), S (100 nM) and Z (20 μM) for 8 h
Result: Eliminated the phosphorylation of RIPK1, RIPK3, and MLKL in human HT-29 cells.
Blocked the phosphorylation of RIPK1, RIPK3, and MLKL in MEFs.

Immunofluorescence

Cell Line: HT-29 cells stably expressing Flag-tagged RIPK3
Concentration: 0.3 μM, 1 μM, 3 μM
Incubation Time: Before the addition of T (40 ng/mL), S (100 nM), and Z (20 μM) for an additional 8 h, HT-29 cells stably expressing Flag-tagged RIPK3 were preincubated with the specified compounds for 2 h
Result: Prevented the generation of RIPK3 puncta.
体内研究
(In Vivo)

Zharp1-163 (5 mg/kg,腹腔注射,一次) 是一种有有效的 RIPK1 抑制剂,可显著保护 C57BL/6 小鼠免受 TNF 诱导的 SIRS 的影响。
Zharp1-163 (5 mg/kg,腹腔注射,一次) 显著减轻了 C57BL/6 小鼠中 Cisplatin 和缺血再灌注诱发的模型中与坏死性凋亡和铁死亡相关的急性肾损伤。

Animal Model: C57BL/6 mice injected TNF.
Dosage: 5 mg/kg
Administration: I.p., pretreated with 30 min prior to challenge
Result: Significantly protected mice from TNF-α-induced lethality and reduced TNF-α-induced temperature loss in these mice.
Significantly ameliorated the production of proinflammatory cytokines, including IL-6.
Induced damage to the cecum and colon.
Animal Model: Cisplatin-induced acute kidney injury in C57BL/6 mice.
Dosage: 5 mg/kg
Administration: I.p., pretreated with 30 min prior to challenge
Result: Significantly inhibited cisplatin-induced body weight loss.
Mitigated mild inflammation and tubular epithelial cell damage.
Decreased the serum creatinine and blood urea nitrogen (BUN) levels in the context of Cisplatin-induced kidney injury.
Animal Model: The left renal artery of C57BL/6 mice pretreated for 2 h was isolated and clamped for 45 min via a nontraumatic artery clamp following right nephrectomy. Reperfusion was subsequently performed.
Dosage: 5 mg/kg
Administration: I.p., 2 h
Result: Significantly inhibited the levels of creatinine and BUN in mouse serum.

化学信息

分子量 393.44
分子式 C21H23N5O3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础